Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in prurigo nodularis with severe pruritus
2020-004198-38Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prurigo nodularis (PN) comparing Vixarelimab with Placebo (2 arms). Primary endpoint: Percent change from baseline in weekly average Worst Itch Numeric Rating Scale at Week 16. Started Mar 2021; status: completed.
02
Drugs
vixarelimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2020-004198-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004198-38.